In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until sickness progression or the individuals are not able to tolerate the study drugs. after which endorse H3K27Ac at this region. Chromatin hyperacetylation could boost https://petery211mxh4.blogginaway.com/profile